MedTrace Logo

Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer

NCT06441994 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-07-31

No results posted yet for this study

Summary

PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II.

Conditions

Interventions

DRUG

PSW-1025

PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211)

Sponsors & Collaborators

  • Japan Agency for Medical Research and Development

    collaborator OTHER_GOV

  • Osaka University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-24
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06441994 on ClinicalTrials.gov